Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience

doi:10.4254/wjh.v8.i22.949

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 22

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8228)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

467

WORD

229

HTML

3646

Tables (1-3)

210

Sum=4552

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1475

Download

2201

Sum=3676

Aug 8, 2016 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Hepatol. Aug 8, 2016; 8(22): 949-956
Published online Aug 8, 2016. doi: 10.4254/wjh.v8.i22.949

Table 1 Baseline characteristics of 834 patients enrolled

Age	Median 57 (range 18-78); age > 65: 18.3%
Sex	Male 64%, female 36%
BMI	Mean 25.6 (± SD) = 3.2 (range 16-39)
Genotype (%)
1a	19.2
1b	79.4
1	1.4
HCV-RNA
HCV-RNA ≤ 10⁶	42%
HCV-RNA > 10⁶	58%
IL 28B (%)¹
TT	21.1
CT	65.4
CC	13.5
Fibrosis (%)
F1	7.7
F2	21.1
F3	33
F4	38.2
Cirrhosis (CTP%)
A5	70.8
A6	23.1
B7	4.5
B8	1.6
Previous treatment (%)
Naive	24.4
Relapser	30.5
Partial responder	14.8
Null responder	30.3
Comorbidity (%)
Diabetes mellitus	11.5
Alcohol	12.1

¹Available on 513 patients (61.5%). BMI: Body mass index; HCV: Hepatitis C virus; IL: Interleukin; CTP: Child-Turcotte-Pugh classification; SD: Standard deviation.

Citation: CLEO Study Group, Ascione A, Adinolfi LE, Amoroso P, Andriulli A, Armignacco O, Ascione T, Babudieri S, Barbarini G, Brogna M, Cesario F, Citro V, Claar E, Cozzolongo R, D’Adamo G, D’Amico E, Dattolo P, De Luca M, De Maria V, De Siena M, De Vita G, Di Giacomo A, De Marco R, De Stefano G, De Stefano G, Di Salvo S, Di Sarno R, Farella N, Felicioni L, Fimiani B, Fontanella L, Foti G, Furlan C, Giancotti F, Giolitto G, Gravina T, Guerrera B, Gulminetti R, Iacobellis A, Imparato M, Iodice A, Iovinella V, Izzi A, Liberti A, Leo P, Lettieri G, Luppino I, Marrone A, Mazzoni E, Messina V, Monarca R, Narciso V, Nosotti L, Pellicelli AM, Perrella A, Piai G, Picardi A, Pierri P, Pietromatera G, Resta F, Rinaldi L, Romano M, Rossini A, Russello M, Russo G, Sacco R, Sangiovanni V, Schiano A, Sciambra A, Scifo G, Simeone F, Sullo A, Tarquini P, Tundo P, Vallone A. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. World J Hepatol 2016; 8(22): 949-956
URL: https://www.wjgnet.com/1948-5182/full/v8/i22/949.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i22.949